200267-65-8

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-b-Amino-4-fluorobenzenepropanol is used as a chiral intermediate for the production of pharmaceuticals that treat conditions such as hypertension and asthma. Its specific configuration ensures the efficacy and safety of the final products.
Used in the Preparation of β-Adrenergic Receptor Agonists:
In the cardiovascular and respiratory industry, (S)-b-Amino-4-fluorobenzenepropanol is used as a key precursor in the preparation of β-adrenergic receptor agonists. These agonists are essential in managing cardiovascular and respiratory conditions.
Used in the Development of Novel Therapeutic Agents:
(S)-b-Amino-4-fluorobenzenepropanol is also investigated for its potential application in the development of new therapeutic agents, showcasing its versatility and importance in the pharmaceutical sector.
Used in Organic Synthesis:
Furthermore, (S)-b-Amino-4-fluorobenzenepropanol serves as an important building block in organic synthesis, highlighting its multifaceted utility in the chemical and pharmaceutical industries.

Upstream product

• 59850-77-0 ethyl 2-amino-3-(4-fluorophenyl) propanoate 
• 18125-46-7 (R)-4-fluorophenylalanine 
• 93939-74-3 (R)-2-(4-fluorophenyl)glycine 
• 122839-52-5 (R)-4-fluorophenylalanine hydrochloride 
• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 459-46-1 4-Fluorobenzyl bromide 

Downstream Products

• 183669-12-7 D,L-N-(tert-butoxycarbonyl)-p-fluorophenylalaninol 
• 1036647-85-4 2-[4-(4-fluoro-benzyl)-4,5-dihydro-oxazol-2-yl]-3-hydroxy-7-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one sodium salt 
• 1036647-87-6 C₂₃H₂₃FN₄O₆S 

Relevant academic research and scientific papers

Thiazolinone unsubstituted quinolines

Thiazolinone quinoline derivatives having no substitution on the quinoline ring active as CDK1 inhibitors which are useful as anti-proliferation agents such as for treating solid tumors.

Azaindole thiazolinones

Azaindole thiazolinone derivatives which demonstrate CDK1 and CDK2 antiproliferative activities and are useful as anti-cancer agents.

Fused purine derivatives

A condensed purine derivative represented by Formula (I): wherein X—Y—Z represents R1N—C═O or N═C—W, R2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X—Y—Z represents R1aN—C═O and R2 represents a substituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a halogen atom, a lower alkylthio group, —NR7R8, —CO2H, a lower alkoxycarbonyl group, —COHal, —CONR9R10 or —CHO, V2 may represent a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group; or a pharmacologically acceptable salt thereof.

Remedies for diabetes

A medicament for the therapeutic treatment of diabetes which comprises as an active ingredient a compound represented by the general formula (I): wherein R1represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aryl gro

Tricyclic erythromycin derivatives

Compounds, or pharmaceutically acceptable salts and esters thereof, of the formula: wherein A, B, D and E, R1, R2, and Z are specifically defined, having antibacterial activity, pharmaceutical compositions containing said compounds, treatment of bacterial infections with such compositions, and processes for the preparation of the compounds.

Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action

A series of benzoxazolamine and benzothiazolamine analogs that inhibit leukotriene (LT) biosynthesis are described.The initial lead, (S)-N-(benzothiazol-2-yl)phenylalanine ethyl ester (5a), was discovered in a screening program for inhibition of Ca-ionophore-A23187-induced LTB4 release in human polymorphonuclear leukocytes (IC50 0.23 μM).Through structural modification, it was determined that hydrophobic substituents in the 5-position and replacement of the phenyl ring of phenylalanine with a cyclohexyl group greatly enhance potency.Several ester bioisosteres that retain potency and enantiomeric selectivity are described.Lead optimization culminated in (S)-N--5-methyl-2-benzoxazolamine (43b), IC50 0.001 μM.The compounds described are not inhibitors of 5-lipoxygenase but, rather, act at the level of arachidonic acid release.